BofA warns Fed risks policy mistake with early rate cuts
Alnylam Pharmaceuticals (NASDAQ:ALNY) Executive Vice President and Chief R&D Officer Pushkal Garg sold shares of the company’s common stock on August 18 and 19, 2025, for a total value of approximately $1.3 million. The sales were executed in multiple transactions with prices ranging from $447.98 to $461.74.
On August 18, Garg sold a total of 1,143 shares in a series of transactions. These shares were sold at weighted average prices ranging from $447.98 to $455.82, totaling $632,758.
On August 19, Garg sold another 1,455 shares in multiple transactions, with prices ranging from $455.41 to $461.74, amounting to $666,987.
In addition to the sales, on August 15, Garg acquired 2,851 shares of Alnylam Pharmaceuticals common stock at $0.00. The acquisition was the result of the vesting of thirty percent of performance-based stock units granted on March 1, 2024, based on the achievement of a clinical milestone.
Following these transactions, Garg directly owns 20,221 shares of Alnylam Pharmaceuticals, Inc. common stock. He also indirectly owns 431 shares by Managed Account and 250 shares by Trust.
These sales were executed under a pre-arranged trading plan pursuant to Rule 10b5-1(c), adopted by Garg on September 11, 2024. Despite current losses, InvestingPro data shows analysts expect the company to turn profitable this year, with 13 analysts recently revising their earnings estimates upward. For deeper insights into Alnylam’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Alnylam Pharmaceuticals reported second-quarter earnings that significantly exceeded analyst expectations. The company posted adjusted earnings of $0.32 per share, outperforming the consensus estimate of -$0.59. Revenue for the quarter reached $773.7 million, surpassing the projected $643.2 million, with total net product revenues rising 64% year-over-year to $672.2 million, primarily driven by the strong performance of AMVUTTRA in ATTR cardiomyopathy. Oppenheimer has upgraded Alnylam Pharmaceuticals to Outperform, highlighting the impressive sales of Amvuttra, which generated approximately $150 million in its first full quarter, far exceeding both Oppenheimer’s estimate of $10 million and the consensus forecast of $17 million. Wolfe Research also upgraded the company’s stock rating to Peerperform, noting better-than-expected patient acquisition capabilities. Meanwhile, Truist Securities reiterated its Buy rating with a price target of $459.00, anticipating the upcoming presentation of zilebesiran KARDIA3 data at the European Society of Cardiology conference. These developments highlight Alnylam’s strong market performance and ongoing progress in its clinical research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.